New pill shows promise for Hard-to-Treat cancers

NCT ID NCT07229898

Recruiting now Disease control Sponsor: Henan Genuine Biotech Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage study tests a new tablet called GEN-725 in 48 adults with advanced solid tumors that have stopped responding to standard treatments. The main goals are to check the drug's safety, how the body processes it, and whether it can shrink tumors. Participants must be between 18 and 75 years old and have no other standard options.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMORS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED SOLID TUMORS

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Cancer Hospital of Shandong First Medical University (Shandong Cancer Institute, Shandong Cancer Hospital)
RECRUITING

Jinan, China
Harbin Medical University Cancer Hospital
RECRUITING

Harbin, China
Shanghai East Hospital
RECRUITING

Shanghai, China
The First Affiliated Hospital of Xinxiang Medical University
RECRUITING

Xinxiang, China